Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies

NCT02116777 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02116777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02116777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
May 16, 2014
Completion date
December 31, 2018
Enrollment
40 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, childhood solid neoplasm, recurrent childhood central nervous system neoplasm, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent malignant solid neoplasm, refractory central nervous system neoplasm